Skip to main content
JAMA Network logoLink to JAMA Network
. 2021 Aug 16;78(10):1278. doi: 10.1001/jamaneurol.2021.2833

Errors in Results and Table 1

PMCID: PMC8369419  PMID: 34398176

The Original Investigation titled “Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: a Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials,”1 published online August 19, 2019, had errors in the Results and Table 1. The number of patients who had a new stroke (ischemic or hemorrhagic) receiving aspirin alone at 90 days should be 459. In addition, the 95% CI for the adjusted hazard ratio for the association of clopidogrel-aspirin and total hemorrhage (major or minor hemorrhage) should be 1.39 to 2.54. This article was corrected online.

References

  • 1.Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurol. 2019;76(12):1466-1473. doi: 10.1001/jamaneurol.2019.2531 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Neurology are provided here courtesy of American Medical Association

RESOURCES